Drug therapy of diabetic neuropathy.
Neuropathy is the most common and perhaps the most devastating complication associated with diabetes. Although many theories regarding the pathogenesis of diabetic neuropathies have been proposed, the most popular theory focuses on the accumulation of sorbitol in the nerve cell through the "polyol pathway." Treatment for diabetic neuropathy remains inadequate. Newer agents such as the aldose reductase inhibitors show some promise in halting and perhaps reversing the pathogenesis of this complication; however, these agents remain investigational. Currently, the most reasonable approach involves the use of agents to control pain and other symptoms associated with this progressive disease.
Brooks
P J
PJ
American Society of Hospital Pharmacists, Bethesda, Maryland.
Francisco
G E
GE
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000927:Anticonvulsants / Q000627:therapeutic use; D002211:Capsaicin / Q000627:therapeutic use; D003929:Diabetic Neuropathies / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D011619:Psychotropic Drugs / Q000627:therapeutic use
D000889:Anti-Arrhythmia Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000927:Anticonvulsants; D011619:Psychotropic Drugs; D000449:Aldehyde Reductase; D002211:Capsaicin